Weekly alert part 1: What are St. Louisans hearing about Ozempic?
Suggested Caption:
For the fourth consecutive week, about 1 in 4 St. Louis adults heard that people with diabetes are not able to access the drug Ozempic because of its recent popularity for weight loss. This week’s total, 27%, is actually up 4% increase from 3 weeks ago. About 45% of older adults (60+ years) have heard this.
Ozempic, also known as semaglutide (a GLP-1 agonist), is a daily or weekly injection approved for diabetes management since 2017. A higher-dose version of the drug (Wegovy), made by the same company, Novo Nordisk, is approved specifically for weight loss.
Where to find out more on this topic: https://www.cbsnews.com/news/ozempic-wegovy-weight-loss-drugs-shortage-prescriptions/
#iHeardSTL #Ozempic #WeightLossMedications #DrugShortages #Diabetes #StayWellSTL
Weekly alert part 2: What are St. Louisans hearing about Ozempic?
Suggested Caption:
Ozempic, also known as semaglutide (a GLP-1 agonist), is a daily or weekly injection approved for diabetes management since 2017. A higher-dose version of the drug (Wegovy), made by the same company, Novo Nordisk, is approved specifically for weight loss.
As doctors and patients noticed that Ozempic also promotes weight loss, there has been a surge in demand for the “off-label” drug among non-diabetic patients seeking to lose weight. This may have led to shortages of the drug, which create serious health risks for people with diabetes.
With the surge in interest in weight loss drugs, doctors have also emphasized the potential risks of their use, including a higher risk of thyroid cancer with long-term use.
Where to find out more on this topic: https://www.cbsnews.com/news/ozempic-wegovy-weight-loss-drugs-shortage-prescriptions/
#iHeardSTL #Ozempic #WeightLossMedications #DrugShortages #Diabetes #StayWellSTL